Wolfe Research Upgrades Intellia Therapeutics (NTLA) to Outperform

Wolfe Research analyst Andy Chen upgraded Intellia Therapeutics (NASDAQ: NTLA) from Peerperform to Outperform with a price target of $21.00.

For an analyst ratings summary and ratings history on Intellia Therapeutics click here. For more ratings news on Intellia Therapeutics click here.

Shares of Intellia Therapeutics closed at $7.23 yesterday.

You May Also Be Interested In

• Northland Upgrades Hyliion Holdings (HYLN) to Outperform 'on Improved Visibility to KARNO Commercialization'
• Johnson Rice Upgrades Core Laboratories (CLB) to Buy
• Wolfe Research Upgrades Biogen (BIIB) to Outperform